Biogenomics Ltd

A vertically integrated biosimilars company backed by the Oman Investment Authority, BioGenomics is focused on diabetes and oncology therapeutics, operating proprietary cell lines capable of producing both drug substance and drug product. The company maintains a robust portfolio and pipeline of advanced insulin analogues, peptides and monoclonal antibodies, alongside a dermatology product targeting diabetic foot ulcers.